Pure Alumina Limited
Pure Alumina Limited (ASX: PUA), is a Sydney-based company, engaged in the production of high purity alumina and gold in Australia. It wholly owns the high-grade Kaolin deposit at Yendon near Ballarat, Victoria and has also developed a hydrochloric acid-based process to extract alumina, purify it, and convert it to high purity alumina. With a market cap of ~ AUD 9.07 million, the PUAâs stock price closed the trading session, on 13th May 2019, at AUD 0.066, up by 24.528% by AUD 0.013. PUA has also generated a YTD return of 15.22%.
Recently, Tolga Kumova and Kitara Investments Pty Ltd increased its shareholding in the company from 6.72% to 9.29% voting power on the purchase of additional 6 million ordinary shares at a price of $0.07 per share. Also, on 9th May 2019, Pure Alumina informed that Polar Sapphire has been operating its pilot plant at full capacity to deliver almost 10 tonnes of 99.999% (5N) high purity alumina (HPA) in the last two weeks, from the date of this announcement. Pure Alumina is currently completing the acquisition of Canada-based HPA producer, Polar Sapphire. Commercial HPA production is scheduled to begin within a year and Pure Alumina plans to undertake R&D to integrate its kaolin process with Polar Sapphireâs proprietary technology.
8common Limited (ASX: 8CO) is into designing and developing software solutions to aid in the control of costs, productivity, and lead generation. The companyâs flagship product expense8 provides travel & expense management and card application & management to large businesses including Broadcast Australia, Woolworths, Amcor and around 117 State and Federal government agencies in Australia.
The companyâs market capitalisation is ~ AUD 26.96 million to date. On 13th May 2019, the 8COâs stock price was down by 5.405%, with the close of the trading session, to AUD 0.175, by AUD 0.010 with ~ 0.87 million shares traded. 8COâs YTD return is also positive at a high of 428.57%.
On 10th May 2019, 8common announced that its wholly owned subsidiary Expense8 has entered into a contract with shared service hub the Federal Department of Industry, Innovation and Science (DIIS) for the provision of Expense8 services. For the quarter ended 31ST March 2019, the company recorded a 72% Year-on-Year increase in revenue to $955K along with cash receipts of $1.066 million, up by more than 87% Year-on-Year.
JCurve Solutions Ltd
JCurve Solutions Limited (ASX: JCS), headquartered in Chatswood, Australia, is a cloud technology company that offers enterprise resource planning (ERP) and telecommunications expense management solutions to clients across New Zealand, Australia and Singapore. With around 327.86 million outstanding shares and a market cap of ~ AUD 11.8 million, the JCSâ stock price closed the dayâs trading session, at AUD 0.038, shooting up 5.556% by AUD 0.002 (as on 13 May 2019). JCSâs three-month return yield is around 33.33%.
Recently, JCurve Solutions announced its half-yearly results for the six months to 31st December 2018 (1H FY19), positioning its business for long term sustainable growth. The consolidated revenue increased by 3% and the consolidated sales by 4% as compared to the prior corresponding period (1H FY18). The EBITDA loss remained consistent at $0.1 million and the cash balance as of the end of half year stood at $3.3 million, up from $2.7 million in the pcp. During the concerned period, the business earned 34 new Australian ERP customers and expensed ~ $0.2 million of investments in R&D to further enhance the Riyo Platform.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.